Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) are types of blood cancer. This study tests a drug called HQP1351 on patients who have these cancers and have not responded well to other medicines called Tyrosine Kinase Inhibitors (TKIs). TKIs are drugs that block cancer cell growth.
In the study, patients will be divided into groups to receive different doses of HQP1351. Some patients might also receive another drug called Blinatumomab, which helps the immune system fight cancer. The study will check the medicine's safety and how it moves through the body.
- Study Duration: Patients will take HQP1351 every two days for 28 days (1 cycle), with some receiving additional cycles.
- Eligibility: Patients must have tried at least two other TKIs and not responded.
- Risks: Close monitoring for side effects, especially in high-dose groups.
Participation involves several visits for tests and monitoring. It's important to discuss with a doctor to understand the potential benefits and risks.